Cardiovascular Risk Stratification of Patients Undergoing Hematopoietic Stem Cell Transplantation: The CARE‐BMT Risk Score
Alexi Vasbinder(University of Washington), Salim S. Hayek(Emory University), Attaphol Pawarode(University of Michigan), Matthew Rochlen(Michigan Medicine), John Maciejewski(University of Michigan), Alina Bardwell(Michigan Medicine), Monika Leja(University of Michigan), Jamie Mills(University of Michigan), Halle Cheplowitz(Rush University Medical Center), Kristen Machado Diaz(Michigan Medicine), Mary Riwes(University of Michigan), Chelsea Meloche(University of Michigan), Rayan Kaakati(University of Michigan), Monalisa Ghosh(Michigan Medicine), Christopher W. Hoeger(Columbia University Irving Medical Center), Danielle Murphy(Rush University Medical Center), Élizabeth Anderson(Wellcome Sanger Institute), Hanna Berlin(University of Michigan), Pennelope Blakely(University of Michigan), Catherine J. Chu(Rush University Medical Center), Husam Shadid(University of Michigan), Radhika Takiar(University of Michigan), Tonimarie Catalan(University of Michigan), Sarah Anand(University of Michigan), Michael Pan(University of Michigan), Gregory A. Yanik(University of Michigan), Ian Pizzo(Michigan Medicine), Brayden Bitterman(Michigan Medicine), Megan Kotzin(Rush University Medical Center), Mousumi Banerjee(University of Michigan), Jeffrey X. Xie(University of Toledo), Daniel Perry(University of Michigan), Yiyuan Huang(Affiliated Hospital of Youjiang Medical University for Nationalities), Tochukwu Okwuosa, Sunita Nathan(Rush University Medical Center), Kishan Padalia(University of Michigan), John Magenau(University of Michigan)
Cited by 25
Related Papers
Factors Associated With Death in Critically Ill Patients With Coronavirus Disease 2019 in the US
|JAMA Internal Medicine|2020|1k
Heterogeneity of genomic evolution and mutational profiles in multiple myeloma
|Nature Communications|2014|906
Association Between Early Treatment With Tocilizumab and Mortality Among Critically Ill Patients With COVID-19
|JAMA Internal Medicine|2020|555
Tisagenlecleucel in adult relapsed or refractory follicular lymphoma: the phase 2 ELARA trial
|Nature Medicine|2021|523